Extensive MET alterations confer clinical response to MET inhibitors in gliomas
Zhao, Z.; Chen, J.; Bao, Z.; Chai, R.; Zhang, K.-n.; Wu, L.; Liu, H.; Mu, Q.; Hu, H.; Zeng, F.; Wang, Z.; Li, G.; Chang, Y.; Wang, Q.; Wu, F.; Zhang, Y.; Liu, Y.; Zhang, W.; Kang, C.; Wang, J.; Tao, R.; Wang, Q.; Jiang, T.
Show abstract
Activating alterations of the MET gene are well-characterized oncogenic drivers, and MET inhibitors could successfully treat several tumor types with MET alterations, including gliomas with PTPRZ1-MET fusion. However, the full diversity and prevalence of MET alterations in gliomas are still lacking to accurately identify a subset of patients likely to benefit from MET inhibitor treatment. Here, we interrogated genomic profiles of 1,351 gliomas, and further identify 60 cases harboring MET alterations, including MET fusions and various MET exon skipping events. MET RNA alterations, but not MET amplification, are highly enriched in the secondary glioblastomas (sGBM) with significantly worse prognosis. Further molecular analysis has shown that MET RNA alterations acting an additive effects of MET overexpression are induced in the course of glioma evolution. In vitro and clinical studies indicate cells and patients harboring MET alterations have better response to MET inhibitors. Collectively, these data suggest that a subgroup of gliomas harboring MET alterations likely to have benefit from MET-targeted therapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Super-Enhancer Driven ZFP36L1 Promotes PD-L1 Expression in Infiltrative Gastric Cancer 94%
- Unveiling chemotherapy-induced immune landscape remodeling and metabolic reprogramming in lung adenocarcinoma by scRNA-sequencing 94%
- Comprehensive characterization of tumor microenvironment in colorectal cancer via histopathology-molecular analysis 94%
Similar papers in this journal
- Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies 94%
- Genomic profiling of cell lines reveals hidden research bias and caveats 93%
- Pan-cancer proteogenomic landscape of whole-genome doubling reveals putative therapeutic targets in various cancer types 92%
Similar papers in this journal
- Distinct Tumor-TAM Interactions in IDH-Stratified Glioma Microenvironments unveiled by Single-Cell and Spatial Transcriptomics 97%
- Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells 95%
- Cellular Reprogramming of H3K27M Pediatric High-Grade Glioma to Neuron-like State 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.